Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 61.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,123 shares of the company's stock after selling 20,607 shares during the quarter. Sterling Capital Management LLC's holdings in Takeda Pharmaceutical were worth $174,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. QRG Capital Management Inc. raised its stake in shares of Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after acquiring an additional 47,490 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $26,000. Franklin Resources Inc. purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $244,000. US Bancorp DE grew its position in shares of Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock worth $1,646,000 after buying an additional 21,744 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after buying an additional 14,831 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 0.5 %

Shares of TAK stock traded down $0.08 on Friday, reaching $15.03. 2,188,239 shares of the stock were exchanged, compared to its average volume of 1,865,662. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $47.82 billion, a price-to-earnings ratio of 37.58, a PEG ratio of 0.24 and a beta of 0.39. The business's 50 day moving average price is $14.72 and its 200 day moving average price is $13.94.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.